Managing patients during major emergency gastrointestinal surgery presents hurdles and challenges. Specifically, surgical patients frequently encounter complications while they recover. Consequently, the FLO-ELA trial investigates if cardiac output-guided therapy improves outcomes. Indeed, effective **Emergency Laparotomy Fluid Management** remains a cornerstone of care because patients are vulnerable. Since outcomes are often poor, researchers designed this trial to find a solution. Moreover, the study aims to establish a protocol for clinicians so that care improves and morbidity decreases.

Furthermore, this trial involved 63 hospitals and used a pilot phase. In addition, investigators recruited participants aged 50 years and above to ensure relevance. First, they used a 1:1 ratio to assign patients to either the intervention or the control group. Next, the study employed a minimisation algorithm to maintain balance. Specifically, this algorithm focused on age and ASA categories so that groups were matched and comparable. Consequently, the trial ensures that both groups are similar. Similarly, the methods aim to minimize bias so the results stay robust and valid.

### Impact of Emergency Laparotomy Fluid Management on Outcomes

Notably, the primary outcome is 'days alive and out of hospital' within 90 days (DAOH-90). In fact, this metric provides a perspective because it measures survival and discharge. Additionally, the plan defines strategies for intercurrent events. Furthermore, the framework addresses secondary outcomes and process measures to provide detail. Moreover, the plan includes analyses to evaluate the pandemic's impact. Specifically, researchers will compare results before and after the Covid-19 onset. Because treatment effects may vary, analysts will also examine subgroups. Therefore, this SAP ensures quality evidence so that it can inform guidelines. Finally, these findings will inform global practices and standards.

FAQs: Understanding the FLO-ELA Trial

What is the significance of the DAOH-90 outcome measure?

DAOH-90 serves as the primary measure. Essentially, it combines mortality and stay duration into one metric. Consequently, it reflects recovery and burden because both factors matter to patients and hospitals.

Why is focus placed on cardiac output-guided therapy?

Clinicians use monitoring to guide fluid dosing. However, this differs from usual care where practitioners rely on blood pressure. Since markers can be unreliable, this approach aims to optimize perfusion so it leads to better outcomes and faster recovery.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgement. Refer to the latest local and national guidelines for clinical practice.

References

Walker NJ et al. Statistical analysis plan for Fluid Optimisation in Emergency Laparotomy (FLO-ELA) Trial; a multi-centre randomised trial of cardiac output-guided fluid therapy compared to usual care in patients undergoing major emergency gastrointestinal surgery. Trials. 2026 Apr 17. doi: 10.1186/s13063-026-09552-3. PMID: 41998794.

Edwards MR et al. Fluid Optimisation in Emergency Laparotomy (FLO-ELA) Trial: study protocol for a multi-centre randomised trial of cardiac output-guided fluid therapy compared to usual care in patients undergoing major emergency gastrointestinal surgery. Trials. 2023;24(1):313. doi: 10.1186/s13063-023-07275-3.